Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-TX-01 for chronic wounds colonized by Pseudomonas aeruginosa
2024-517491-38-00Phase 2Authorised
- Sponsor
- PathoBlock Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of PB-TX-01 in chronic wound colonized by Pseudomonas aeruginosa (2 arms), sponsored by PathoBlock Therapeutics. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Reduction of Pseudomonas aeruginosa bacterial load. Planned start Oct 2026; status: authorised.
02
Drugs
PB-TX-01
03
Conditions
chronic wound colonized by Pseudomonas aeruginosa
Beyond the preview
Go deeper on 2024-517491-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517491-38-00.